trial summary · NCT07872020
SYMmetric Valve fraME Expansion To Reduce hYpoattenuated Leaflet Thickening After Balloon-expandable TAVI: the SYMMETRY Trial
Trial record from the TrialBase DB dataset, status RECRUITING, condition Aortic Valve Stenosis and/or Insufficiency, sponsored by Erasmus Medical Center. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
Rationale: Transcatheter aortic valve implantation (TAVI) has become the standard of care for aortic stenosis across all surgical risk categories, including low-risk, younger patients (≥70 years). As many of these patients are expected to outlive their prosthetic valves, the durability of the valve becomes an increasingly critical factor. Hypoattenuated leaflet thickening (HALT), a finding on post-TAVI computed tomography (CT), occurs in approximately 20% of patients and is associated with bioprosthetic valve dysfunction. Balloon-expandable valves seem more susceptible to HALT with an occurrence rate of 21%, compared to 16% for self-expanding valves. A recent study identified underexpansion of the transcatheter heart valve prosthesis as a key predictor of HALT at 30 days, which in turn was associated with a sixfold increase in cardiovascular mortality and a threefold increase in all-cause mortality at 1 year. Moreover, data suggest that, in the absence of post-dilatation, more than 95% of balloon-expandable valve implants exhibit some degree of underexpansion. In contrast, routine post-dilatation enhances valve expansion and hemodynamic performance without significantly increasing adverse events. The double-TAP technique-re-inflation of the TAVI delivery balloon after initial valve deployment-achieves a 9-10% increase in valve frame expansion, potentially reducing HALT risk and improving long-term outcomes. Objective: To determine whether routine double-TAP post-dilatation after balloon-expandable TAVI is safe and can reduce the incidence of HALT. Study design …
Source record: https://clinicaltrials.gov/study/NCT07872020
Facts
| registry id | NCT07872020 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | not reported |
| study type | INTERVENTIONAL |
| lead condition | Aortic Valve Stenosis and/or Insufficiency |
| sponsor | Erasmus Medical Center |
| sponsor class | OTHER |
| enrollment | 422 |
| start date | 2026-10-26 |
| primary completion | 2028-11-01 |
| completion | 2033-11-01 |
| results posted | not reported |
Conditions
- Aortic Valve Stenosis and/or Insufficiency
- Hypoattenuated Leaflet Thickening
- Valve Expansion
- Transcatheter Aortic Valve Replacement
Interventions
- Double-TAP post-dilatation
Countries
- Germany
- Netherlands
Intervention types: PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.